Pages that link to "Q36354099"

The following pages link to Radiation combined with EGFR signal inhibitors: head and neck cancer focus (Q36354099):

Displaying 30 items.

• Altering the response to radiation: sensitizers and protectors (Q26865377) (← links)
• Found in translation: Integrating laboratory and clinical oncology research (Q28744471) (← links)
• Halofuginone enhances the radiation sensitivity of human tumor cell lines (Q33717031) (← links)
• Broad phenotypic changes associated with gain of radiation resistance in head and neck squamous cell cancer (Q33768197) (← links)
• Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer (Q33990915) (← links)
• Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape (Q34194706) (← links)
• Impact of oncogenic K-RASon YB-1 phosphorylation induced by ionizing radiation (Q35558949) (← links)
• Energy metabolism in a matched model of radiation resistance for head and neck squamous cell cancer (Q35733884) (← links)
• Personalized Combined Modality Therapy for Locally Advanced Non-small Cell Lung Cancer (Q36089579) (← links)
• Ligand-dependent responses of the ErbB signaling network: experimental and modeling analyses (Q36254464) (← links)
• Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status (Q36484536) (← links)
• The epidermal growth factor receptor (EGFR) in head and neck cancer: its role and treatment implications (Q36488138) (← links)
• Epidermal growth factor receptor inhibition and non-small cell lung cancer (Q36504349) (← links)
• Posttranslational protein modifications: current implications for cancer detection, prevention, and therapeutics (Q36537788) (← links)
• Targeting epidermal growth factor receptor signaling in the treatment of head and neck cancer (Q36613969) (← links)
• Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer orthotopic model. (Q36755155) (← links)
• Combination of radiotherapy with EGFR antagonists for head and neck carcinoma (Q36795322) (← links)
• Opportunities for improving the therapeutic ratio for patients with sarcoma (Q36836263) (← links)
• Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer (Q37097424) (← links)
• Review of cetuximab in the treatment of squamous cell carcinoma of the head and neck (Q37160382) (← links)
• Receptor signaling as a regulatory mechanism of DNA repair (Q37368256) (← links)
• Overview of current and future biologically based targeted therapies in head and neck squamous cell carcinoma (Q37414399) (← links)
• Lack of Cetuximab induced skin toxicity in a previously irradiated field: case report and review of the literature (Q37755493) (← links)
• Consistency Test of the Cell Cycle: Roles for p53 and EGR1 (Q37982353) (← links)
• Targeted therapy in head and neck cancer (Q37988981) (← links)
• Comparative hyperthermia effects of silica-gold nanoshells with different surface coverage of gold clusters on epithelial tumor cells. (Q38831110) (← links)
• Molecular Targeting of Growth Factor Receptor Signaling in Radiation Oncology (Q38869420) (← links)
• High incidence of oral dysesthesias on a trial of gefitinib, Paclitaxel, and concurrent external beam radiation for locally advanced head and neck cancers. (Q46211576) (← links)
• A Phase II Study of Gefitinib for Aggressive Cutaneous Squamous Cell Carcinoma of the Head and Neck (Q54535177) (← links)
• Synergistic antitumour activity of HDAC inhibitor SAHA and EGFR inhibitor gefitinib in head and neck cancer: a key role for ΔNp63α (Q91597632) (← links)